Clinical Trial Update: Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Gefitinib (Iressa) for first relapse prostate cancer after prostatectomy or radiotherapy has completed. This update summarizes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED